Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma
Wenxin Shen, Qianlan Zhou, Qinzhen Zhang, Lina Han, Li Chen, Xiaowen Li, Bing Dai, Si Liu, Lishen Shan
Abstract
KEY POINTS: Omalizumab enables children who are intolerant to AIT to initiate AIT successfully. Combination therapy better improves asthma and rhinitis symptoms, FeNO, and lung function compared to single SCIT or omalizumab treatment. Combination therapy reduces the incidence of adverse reactions during the initial phase of SCIT and enhances its safety.
Topics & Concepts
OmalizumabMedicineAsthmaAllergic asthmaIncidence (geometry)Allergen immunotherapyAdverse effectLung functionAllergenImmunotherapyIntensive care medicineAllergyImmunologyImmunoglobulin EInternal medicineLungAntibodyImmune systemPhysicsOpticsAsthma and respiratory diseasesAllergic Rhinitis and SensitizationRespiratory and Cough-Related Research